Anthos Therapeutics Launches Second Phase III Clinical Trial of Its Dual-Acting Factor XI Inhibitor, Abelacimab

Anthos Therapeutics announced the initiation of recruitment for its second Phase III clinical trial investigating abelacimab, its novel dual-acting fully human monoclonal antibody targeting both Factor XI and Factor XIa.